FY2025 · ended Dec 31, 2025 · Revenue $5,000, -50.0% YoY · Filed Mar 31, 2026
Alaunos Therapeutics, Inc. (TCRT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $5,000 and a net loss of $4.2 million. Free cash flow was -$3.0 million.
Revenue (TTM)
$3,000
-50.0% vs year-ago TTM
Net income (TTM)
$-4.01M
-0.4% vs year-ago TTM
Operating cash flow (TTM)
$-2.73M
+4.2% vs year-ago TTM
Free cash flow
$-2.97M
+40.3% vs prior year
EPS (TTM)
$-1.73
+30.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.40M
+1.0% vs prior year
Net cash
$1.09M
FY 2024
Operating margin
-135233.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TCRT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fort Lauderdale, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1107421
- Former names
- ZIOPHARM ONCOLOGY INC (until Jan 4, 2022); EASYWEB INC (until Sep 19, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5,000 | $10,000 | $5,000 | $2.9M | $398,000 |
| Operating income | -$4.2M | -$4.8M | -$34.3M | -$35.1M | -$77.5M |
| Net income | -$4.2M | -$4.7M | -$4.7M | -$37.7M | -$78.8M |
| Diluted EPS | -$2.20 | -$2.92 | -$21.97 | -$2.61 | — |
| Operating cash flow | -$2.9M | -$5.0M | -$30.1M | -$29.2M | -$61.5M |
| Free cash flow | -$3.0M | -$5.0M | -$30.3M | -$29.4M | -$64.8M |
| Total assets | $3.0M | $2.8M | $8.3M | $64.9M | $94.9M |
| Total liabilities | $813,000 | $692,000 | $2.0M | $26.4M | $36.8M |
| Stockholders' equity | $2.2M | $2.1M | $6.3M | $38.6M | $58.1M |
| Cash and investments | $1.4M | $1.1M | $6.1M | $39.1M | $76.1M |
| Total debt | — | $0 | $0 | $22.3M | $34.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Listing notice
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Listing notice
|
Oct 9, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 22, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Sep 17, 2026 | Sep 16, 2026 |
All 1000 Alaunos Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.